CHThe article reports that the pharmaceutical company MSD is currently the largest taxpayer in Switzerland, contributing more taxes than Roche and Novartis combined. This financial contribution is attributed to a single medication, highlighting its significant economic impact. However, the situation is complicated by U.S. President Donald Trump's potential claim over these funds, suggesting international tensions over tax revenue. The article emphasizes the unusual concentration of tax contributions from a single drug and the geopolitical implications.
Tendenz-Einschätzung (Links): The article frames the issue of tax contributions as a matter of national interest and highlights the potential interference from U.S. politics, which could be seen as a challenge to Swiss sovereignty. While it presents facts neutrally, the emphasis on Trump’s potential claim introduces a narrative,
